Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Manfrini

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Tumori|April 25, 2000
Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor responseS Ferrari, M Mercuri, P Picci, et al.
Multiple Sclerosis and Related Disorders|October 11, 2020
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosisH-P Hartung, T Berger, R A Bermel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremitiesP Picci, T Böhling, G Bacci, et al.
Blood Cancer Journal|July 4, 2015
Fanconi anemia gene variants in therapy-related myeloid neoplasmsM T Voso, E Fabiani, Z Zang, et al.
Leukemia|July 1, 2017
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosisG Martinelli, M Mancini, C De Benedittis, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Tumori|April 25, 2000
Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor responseS Ferrari, M Mercuri, P Picci, et al.
Multiple Sclerosis and Related Disorders|October 11, 2020
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosisH-P Hartung, T Berger, R A Bermel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremitiesP Picci, T Böhling, G Bacci, et al.
Blood Cancer Journal|July 4, 2015
Fanconi anemia gene variants in therapy-related myeloid neoplasmsM T Voso, E Fabiani, Z Zang, et al.
Leukemia|July 1, 2017
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosisG Martinelli, M Mancini, C De Benedittis, et al.
Pageof 9